AI-powered chronic disease treatment platform Synapsor has recently completed a fresh round of financing worth tens of millions of dollars, with Xiaomi reportedly serving as lead investor, alongside co-investors Source Code Capital and Shunwei Capital. The funds are to be used for research and development of core products and algorithms, capacity improvement and business expansion in both the Chinese and overseas markets.
Previously, Synapsor received angel investment as high as tens of millions of yuan from Source Code Capital. This fundraising attracted Xiaomi and Shunwei Capital, and retained existing shareholder Source Code Capital. In 2021, Synapsor has raised nearly 100 million yuan in financing.
Beijing Synapsor Industrial Intelligent Technology Co., Ltd. was founded by a technical team with backgrounds at Oxford University on October 25, 2019. The company is committed to the R&D and manufacturing of AI-powered smart medical wearable devices.
Currently, U.S. enterprises and their products occupy a dominant position in the wearable AI medical equipment market. U.S. products are advanced in technology, but also come with a high price tag, making it difficult for mass consumers in the Chinese market to buy them repeatedly. Synapsor has self-developed hardware devices from in-depth algorithms, and employed its industry-leading algorithm technology and R&D strengths in the sensor field to mass produce wearable AI medical devices for universal use.
In addition, based on data collected by the hardware, Synapsor issues early warnings to patients in critical situations through evidence-based AI, and effectively reduces the risk of users encountering unexpected situations. The smart terminal can summarize and analyze data in the cloud and deliver reports to patients’ families and doctors, thereby enabling convenient communication between all parties.